Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid Antigen Testing for SARS-CoV-2 Could Effectively Control COVID-19 Outbreak, Finds Study

By LabMedica International staff writers
Posted on 30 Aug 2021
Rapid COVID-19 antigen tests that permit new cases to isolate immediately can be important surveillance tools and effectively control COVID-19 outbreaks, according to a longitudinal comparison between antigen tests performed at home and quantitative real-time polymerase chain reaction (qRT-PCR).

Researchers at E25Bio, Inc. More...
(Boston, MA, USA), LabCentral, Inc. (Boston, MA, USA), Harvard T. H. Chan School of Public Health (Boston, MA, USA), Mount Sinai School of Medicine (New York, NY, USA), and BioInnovation Labs, LLC (Cambridge, MA, USA) sought to validate the effectiveness of direct antigen rapid tests (DARTs) and to test whether at-home testing with DART could prevent the spread of SARS-CoV-2 in a co-working environment. The team conducted a study of high-frequency testing using inexpensive, at-home, semi-quantitative, DARTs and compared their performance with that of qRT-PCR on self-collected nasal specimens.

For the study, a total of 257 participants were enrolled who self-collected nasal swab specimens twice weekly at home during a six-month period. DART was performed at home, and the findings were compared with laboratory qRT-PCR tests. A total of 2,951 pairs of nasal swabs were self-collected by participants and tested by qRT-PCR and DART. The researchers found that that twice-weekly surveillance with DART detected infections in 15 individuals, with 96.3% sensitivity on days 0 through 3 of symptoms. Detection on day 3 is almost as effective as detection on day 1 for reducing the incidence of COVID-19, if 75% of a population is surveilled. The prevalence of disease dictates the frequency of testing and its effectiveness for controlling potential outbreaks.

COVID-19 outbreak management has been hindered by high transmission rates and limitations in testing capacity. Effective public health tools are needed for rapid and early detection. The current diagnostic standard is qRT-PCR, although its cost and long turnaround times limit its utility for widespread surveillance. However, frequent at-home testing with DART allows infected individuals to be identified and quarantined immediately. Such surveillance can prevent viral transmission in in-person work environments or other social settings, effectively controlling COVID-19 outbreaks, according to the researchers.

Related Links:
E25Bio, Inc.
LabCentral, Inc.
Harvard T. H. Chan School of Public Health
Mount Sinai School of Medicine
BioInnovation Labs, LLC



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.